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Overdose Prevention and Naloxone Prescription
for Opioid Users in San Francisco
Lauren Enteen, Joanna Bauer, Rachel McLean, Eliza Wheeler,
Emalie Huriaux, Alex H. Kral, and Joshua D. Bamberger
ABSTRACT Opiate overdose is a significant cause of mortality among injection drug users
(IDUs) in the United States (US). Opiate overdose can be reversed by administering
naloxone, an opiate antagonist. Among IDUs, prevalence of witnessing overdose events is
high,andtheprovisionoftake-homenaloxonetoIDUscanbeanimportantinterventionto
reduce the number of overdose fatalities. The Drug Overdose Prevention and Education
(DOPE) Project was the first naloxone prescription program (NPP) established in
partnershipwithacountyhealthdepartment(San FranciscoDepartmentofPublicHealth),
and is one of the longest running NPPs in the USA. From September 2003 to December
2009, 1,942 individuals were trained and prescribed naloxone through the DOPE Project,
of whom 24% returned to receive a naloxone refill, and 11% reported using naloxone
during an overdose event. Of 399 overdose events where naloxone was used, participants
reported that 89% were reversed. In addition, 83% of participants who reported overdose
reversal attributed the reversal to their administration of naloxone, and fewer than 1%
reportedseriousadverse effects.Findings from the DOPEProjectaddto a growingbodyof
research that suggests that IDUs at high risk of witnessing overdose events are willing to be
trained on overdose response strategies and use take-home naloxone during overdose
events to prevent deaths.
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INTRODUCTION
Drug-related deaths are the leading cause of injury mortality among all US adults
aged 35 to 55.
1 Opioids are one of the most commonly involved substances in single
and polydrug use deaths.
2 Opiate overdose is the single greatest cause of mortality
among injection drug users (IDUs) in the USA
3 and accounts for more than half of
all deaths among opiate injectors, far exceeding the proportion due to HIV/AIDS
and viral hepatitis.
3,4 Opiate overdose deaths increased by 529% between 1990 and
2003 across the USA.
2 In addition, opioid analgesic-related deaths are among the
fastest growing causes of drug poisoning deaths in the USA.
1
While loss of consciousness following overdose can at times be instantaneous,
death is usually the result of cardiac arrest that follows hypoxia, which is the result of
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931the opiatesuppressingthe centralrespiratorydrive.
5,6 The time from initial injection to
death typically leaves a 1–3-h window for a witness to intervene.
5,6 While this
window would leave sufﬁcient time for emergency personnel to respond, studies
report that emergency medical services (EMS) are activated in fewer than half of
overdose events.
7–9 Although cardiopulmonary resuscitation can be an effective
intervention during an overdose event,
10 opiate overdose can almost universally be
reversed by the administration of naloxone—a legal, nonscheduled opioid antagonist
that can be quickly administered by intramuscular injection.
10–12 Naloxone produces
no symptoms of dependence or tolerance and, in the absence of narcotics, has no
pharmacological activity.
13 Naloxone is routinely administered by emergency services
personnel to revive opiate overdose victims, and serious side effects are rare.
14–17
Yet, barrierstointerventionandoverdosereversalremain.Between1997 and 2000,
EMS response was noted in medical examiner's notes for only 26% of fatal opiate
overdoses in San Francisco.
8 In surveys, IDUs consistently report a high prevalence of
witnessing overdose events,
9,18–22 and in one Bay Area survey, 89% of participants
reported witnessing an overdose event.
9 However, IDUs also report reluctance to
contact EMS as a witness.
9,21–25 Qualitative research with IDUs indicates that fear of
police is a signiﬁcant barrier to calling emergency services (“9-1-1” in the USA) during
an overdose event.
21,23 IDUs report making other attempts to revive overdose victims
without EMS assistance,
9,21,22 and demonstrate willingness to administer naloxone
during an overdose if it was made available to them directly.
9,18,23,24 This indicates
that targeted take-home naloxone prescription and overdose training programs may
be an effective intervention to reduce opiate overdose deaths.
In response to increased fatal opiate overdose, community-based programs
began distributing naloxone directly to IDUs in Europe in 1995,
26 and underground
programs have been distributing naloxone in the USA since 1999.
27 Take-home
naloxone prescription programs (NPPs) are currently in place in locales throughout
the USA, including large-scale NPPs in Chicago, Baltimore, New York City, New
Mexico, and Massachusetts.
27–29 NPPs typically provide overdose response
education and naloxone administration training to IDUs and others at high risk of
witnessing an opioid overdose, so that participants are able to administer naloxone
safely and avert fatalities during overdose events.
Preliminary evaluations of NPPs in several cities have found that overdose
response education and naloxone administration training positively affects IDUs’
ability to recognize overdose symptoms and identify cases where naloxone is
indicated.
24,28–30 Prospective pilot studies in Los Angeles
32 and New York
23,33 and
San Francisco
30 tracked small samples of IDUs who were trained and provided with
naloxone. In New York and San Francisco, over half reported using naloxone
during 3- or 6-month follow-up periods, and the proportion of participant-
conﬁrmed reversals ranged from 74%
32 to 100%.
23,30,33
Fewer studies have examined outcomes of an NPP over an extended period of
time. One longstanding NPP in Chicago reported training 3,500 participants from
2001 to 2005, of whom 319 reported overdose reversals (9%).
27 A program
dispending intranasal naloxone in Massachusetts recently reported that 19% (74) of
385 trained participants used naloxone after training.
34
In 2003, the San Francisco Department of Public Health (SFDPH) partnered
with a community-based program, the Drug Overdose Prevention and Education
Project (DOPE Project) to establish the ﬁrst health-department sanctioned NPP in
the US. Modeled on underground community based NPPs, the DOPE Project was
the ﬁrst NPP to receive staff and support from a county department of public health.
ENTEEN ET AL. 932The goal of the DOPE Project is to integrate overdose prevention education and
naloxone distribution into all settings serving people at risk for opioid overdose.
31
We present evaluation ﬁndings for the DOPE Project NPP in San Francisco,
from the start of SFDPH partnership in September 2003 through December 2009.
Our goal was to examine the number and demographics of trained participants
prescribed take-home naloxone, as well as the prevalence of and reasons for
receiving naloxone reﬁlls among trained participants. We present prevalence of
naloxone administration among individuals receiving reﬁlls from the DOPE Project
and outcomes of naloxone administration, including any negative effects reported
and overall proportion of successful reversals.
METHODS
The San Francisco DOPE Project Intervention
Since September 2003, DOPE Project staff and SFDPH medical providers have
trained and distributed naloxone at sites throughout San Francisco that include
syringe exchange programs (SEP), re-entry programs, pain management clinics,
methadone maintenance and buprenorphine treatment programs, and single room
occupancy (SRO) hotels. The DOPE Project currently conducts trainings and
naloxone dispensations approximately eight times per month throughout San
Francisco.
Participants are usually recruited and trained while waiting to receive services at
clinics, dropping off syringes at SEPs, or in group trainings in SROs and treatment
programs. Trainings typically last between 10 and 30 minutes and focus on overdose
symptom identiﬁcation, revival strategies, calling EMS, and administering naloxone
(Figure 1). After DOPE Project staff train participants, SFDPH medical providers
initiate a medical record (clinical registration) and assign each participant a unique
identiﬁer. Providers prescribe and dispense naloxone in two 0.4-mg/mL vials and
two 3-cm
3/mL 22-gauge 1-in muscling syringes along with a rescue breathing mask.
All trained participants with unique identiﬁers and clinical registrations may receive
reﬁlls of two pre-ﬁlled syringes at any subsequent dispensation—when participants
use naloxone, lose, or have naloxone conﬁscated. SFDPH providers do not limit the
number of reﬁlls trained participants may receive.
Data Collection
All participants who receive take-home naloxone complete a brief questionnaire
immediately following initial training. The questionnaire is voluntary, self-reported,
and administered by DOPE Project or SFDPH staff. Information provided includes
date of birth, gender, race/ethnicity, primary language, homeless status, and/or
current housing.
All participants who receive subsequent reﬁlls also complete an additional brief
questionnaire. If receiving naloxone following a loss, participants describe “circum-
stances of loss (e.g., stolen bag, taken by police, etc.).”
Participants who receive reﬁlls following naloxone administration complete a
brief interview with DOPE Project staff. The standard questionnaire captures
information about to whom naloxone was administered (e.g., “girlfriend,”
“spouse,”“ friend,”“ stranger,”“ self”), and whether participants used other
prevention strategies covered in DOPE Project training: sternum rub; awaken
victims; call emergency services; rescue breathing; waited with them. Participants are
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outcomes for the event: they [victim] woke up without any help; they woke up
because of my help; paramedics came and revived the person [victim]; paramedics
came and I do not know what happened next; they [victim] died; do not know; other
(specify). Participants report any “negative consequences” of the overdose and
naloxone administration that include: arrest of victim or witness; vomiting;
harassment by police; harassment by paramedics; seizure; other (specify).
Analysis
All records used in this study were obtained as part of the DOPE Project routine
program monitoring and evaluation. We considered all individuals who were
trained, prescribed, and assigned a unique identiﬁer (at clinical registration) as
participants in the DOPE Project and used a clinical registration database (Microsoft
Excel, Seattle, WA, USA) to calculate total number of trained participants, and
participant demographics. Participants who reported being homeless, living at a
shelter, transitional housing, or street or “couch surﬁng” were coded as unstably
housed.
A separate database of all reﬁlls is also maintained by the DOPE Project
(Microsoft, Excel, Seattle, WA). Databases were linked by participants’ unique
identiﬁers to determine the number of unduplicated participants who received reﬁlls
following self-reported loss or use of naloxone, as well as the total number of losses
and naloxone use reported, the proportion of individuals receiving multiple reﬁlls,
and the proportion of individuals reporting multiple naloxone use. We excluded
from analysis any records of reﬁlls where no unique identiﬁer could be linked to an
existing clinical registration (n=37).
We coded reports stating that naloxone was taken by police, San Francisco
Department of Public Works (DPW) or sheriff’so f ﬁce as conﬁscation; all reports
that naloxone was stolen, lost, or destroyed for any reason was coded as being lost.
We use information captured in reﬁll questionnaire to determine outcomes for
trained participants who reported administering naloxone. Questionnaires were
used to determine proportion of participants who used strategies other than
naloxone, including contacting EMS. All events where participants reported that
the victim was “revived” after naloxone administration are included here as
Mechanism of opiate overdose 
Risk factors for opiate overdose
Prevention strategies 
Recognition 
Response 
Calling 9-1-1 
Administration of naloxone 
Rescue breathing 
Aftercare 
Naloxone care 
Logistics and refills 
FIGURE 1. Components of 10−30-min trainings conducted by DOPE Project staff for all
participants receiving take-home naloxone.
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to naloxone administration. Questionnaires were also used here to report
proportion of deaths, unknown outcomes, or any negative effects.
RESULTS
From September 2003 to December 2009, the DOPE Project and SFDPH medical
providers trained and prescribed naloxone to 1,942 unduplicated individuals in San
Francisco. The number of new participants increased steadily from 2003 to 2009,
averaging 328 per year.
The majority of participants were male (64%) and the median age at training
was 40 years old (Table 1). Race/ethnicity was only captured for 75% of
participants overall. Of these, 61% were Caucasian and 18% were African
American. Housing status was reported by 88% of participants, of whom over half
(59%) reported being homeless or unstably housed (not shown).
Of the 1,942 participants who receive naloxone prescriptions, 24% returned to
receive at least one naloxone reﬁll (Table 2), of whom half returned on more than
one occasion to receive multiple reﬁlls. Participants requested reﬁlls for a variety of
reasons, including having naloxone stolen on the street, conﬁscated in a shelter, or
destroyed during unstable housing transition. Of 1,020 reﬁlls dispensed, 399 (40%)
were provided after participants reported using naloxone during an overdose event,
TABLE 1 DOPE Project participants trained and prescribed 2003−2009 (n=1,942)
n (%)
Gender
Male 1,239 (64)
Female 644 (33)
Transgender 15 (1)
Unknown (not captured) 44 (2)
Race/ethnicity
Caucasian/White 901 (46)
African American/Black 263 (14)
Latino/a 131 (7)
Asian/Paciﬁc Islander 32 (2)
Native American 35 (2)
More than one race/ethnicity 53 (3)
Other 51 (3)
Unknown (not captured) 476 (24)
Housing status
Stable housing 618 (32)
Homeless/unstably housed
a 893 (46)
Living in shelter 127 (7)
Living in transitional housing 292 (15)
Living on street 241 (12)
Doubling up or “couch surﬁng” 51 (3)
Homeless, no additional housing information 182 (9)
Unknown housing status 431 (22)
aIncludes both those who answered “yes” to homeless and those reporting living in shelter, transitional
housing, or doubling up
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were provided after participants reported conﬁscation by police, DPW, or sheriff’s
department (upon admission to jail). Of participants who lost naloxone, 27%
reported that they also used naloxone in response to a subsequent overdose event.
Overall, 11% of all participants reported using naloxone during an overdose
event, and 5% reported using multiple prescriptions (reﬁlls) during more than one
overdose event (Table 2). In addition, a small proportion of participants (not shown)
reported using multiple naloxone doses to reverse as many as eight separate
overdose events. The cumulative number of naloxone-administration events
reported to the DOPE Project has risen steadily since 2004 (Figure 2), with an
average of 80 events reported annually.
In 83% of overdose responses reported, participants stated that naloxone
administration reversed the overdose. Participants reported successful outcomes
(reversal with or without EMS involvement) for 89% of all overdose events where
TABLE 2 Participants who received reﬁlls from the DOPE Project, 2004−2009
n (%)
Participants who received at least
one naloxone reﬁll, any reason
470 (24)
Participants who received multiple
reﬁlls, any reason
219 (11)
Participant who received at least one
reﬁll reporting naloxone loss
311 (16)
Participants who received at least one
reﬁll reporting conﬁscation
79 (4)
Participants who received at least one
reﬁll reporting naloxone administration
during an overdose event
215 (11)
Participants who received multiple
reﬁlls reporting naloxone administration
during multiple overdose events
95 (5)
Of 1,942 participants trained 2003−2009
0
50
100
150
200
250
300
350
400
450
2003 2004 2005 2006 2007 2008 2009
Cumulative number of naloxone administrations during overdose events
reported to the DOPE Project, by year
FIGURE 2. Cumulative number of opioid overdose responses with naloxone reported by DOPE
Project participants receiving reﬁlls, by year, 2003−2009.
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was contacted, but outcome was unknown.
Three-quarters of participants who used naloxone also reported using
complementary overdose prevention strategies taught by the DOPE Project such as
rescue breathing (50%, Table 3). However, a minority (29%) reported calling
emergency services, and only 21% of reports included indication that EMS arrived.
Although only one participant reported arrest following naloxone administration,
13% of the 84 participants who reported ambulance response also reported some
harassment by police or EMS (Table 3).
Serious adverse effects were reported rarely and included several instances of
seizures (Table 3). In cases for which participants reported a known outcome,
vomiting was the most commonly reported negative effect (13%), followed by
“anger” or discomfort expressed by victim upon waking (9%). Three participants
(G1%) reported witnessing a victim experience symptoms of a seizure following
naloxone administration. Victim death was reported by participants in four (1%)
events where naloxone was used (not shown). In three of these cases, participants
reported that the victim had been unconscious for an undetermined amount of time
TABLE 3 Participant reported responses and outcomes of opioid overdose events where
naloxone was administered, among participants receiving a naloxone reﬁll from the DOPE
Project, 2004–2009 (n=399)
N (%)
Relationship between participant and overdose victim
Participant used naloxone on companion (friend, spouse) 142 (36)
Participant used naloxone on stranger 60 (15)
Relationship between participant and victim not reported 111 (28)
Participant reported naloxone was used on self during overdose 85 (21)
Other overdose prevention strategies used in addition to naloxone
Participant reported using any additional strategy 298 (75)
Sternum rub 123 (31)
Awaken victim 127 (32)
Rescue breathing 199 (50)
Participant reported calling 911 during the overdose event 116 (29)
Participant reported ambulance response 84 (21)
Participant reported outcome of overdose event
Reversed, all reasons 357 (89)
Reversed due to participant administering naloxone 333 (83)
Reversed following EMS response 19 (5)
Naloxone administered, but victim revived by another method 5 (1)
Victim died 6 (2)
Outcome Unknown 36 (9)
Other adverse outcomes reported
Seizure 3 (1)
Vomiting 50 (13)
Victim was angry or “dope sick” 36 (9)
Arrest 1 (.2)
EMS/police harassment 11 (3)
Of 399 overdose events where participants administered naloxone, as reported to DOPE Project by
participants receiving naloxone reﬁlls, 2004−2009
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public park.
DISCUSSION
These ﬁndings are the ﬁrst to examine overall participant demographics for a
longstanding NPP, and indicate that the DOPE Project is well targeted to reach
participants who are at high risk of overdose. For example, we found that 46% of
those trained by the program identiﬁed as unstably housed or homeless, which has
been associated with signiﬁcantly elevated risk of overdose death in previous studies
of overdose in San Francisco.
29 Moreover, by targeting the program in places where
there is a high prevalence of IDUs who witness overdose events, the DOPE Project
has trained a steady population of newly prescribed participants, many of whom
return to receive reﬁlls on multiple occasions, which further indicates that they are
not only willing to be trained, but also motivated to keep a naloxone supply
available for use during an overdose.
We found a substantial proportion of trained participants who reported using
naloxone, and the proportion found here was consistent with reports from the
Chicago Recovery Alliance, one of the largest NPPs in the USA.
27 Additional
previous studies have focused on prospectively tracked small samples and targeted
follow up,
23,30,32,33 making utilization and reversal rates difﬁcult to compare to our
ﬁndings. However, that these studies consistently ﬁnd high proportions of
participants reporting naloxone use at follow up may suggest that the proportion
of participants who report naloxone utilization at reﬁll is an underestimate of the
overall proportion of participants who use naloxone after training.
We found that the majority of individuals who used naloxone during an
overdose event also indicated that they used other revival methods taught during
DOPE trainings. However, a minority reported contacting EMS. An earlier survey of
IDUs in San Francisco found that 62% reported they would be “less inclined” to
contact EMS if they had naloxone.
8 That 84% of participants who used naloxone
reported successful reversal without EMS intervention may suggest that IDUs did
not call EMS because they did not deem it necessary, given successful reversal.
Among participants who did not know the outcome of the overdose event, calling
EMS was more common. Nevertheless, calling emergency services is an important
component of training, and efforts should continue to be made to assess and address
IDU barriers to contacting EMS during an overdose event, as well as continuing to
provide naloxone education and prescription.
Among participants who reported using naloxone, the majority reported
positive and successful experiences. Findings here on rates of success per event
reported were within the range found in previous studies.
32,34 Reports of adverse
events were rare (G1% reported victim seizure following naloxone administration).
In addition, although six deaths were reported, there was no indication that this was
due to naloxone administration and may have been cases where individuals had
been experiencing the overdose for several hours before a witness arrived. Our
ﬁndings indicate that IDUs can and will successfully administer naloxone with brief
training, intervening during overdose events that may otherwise be fatal.
Limitations
There were several methodological limitations that we encountered while interpret-
ing our ﬁndings. All information is self-reported by participants and could be
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questionnaire. Due to participant non-disclosure, missing information about race/
ethnicity and housing status made it difﬁcult to assess any trends in reﬁll receipt or
naloxone use by these characteristics. Findings reported about naloxone admin-
istration and outcome excluded seven reports where unique identiﬁers could not be
matched to clinical registrations. However, no serious adverse outcomes were
reported in excluded records.
Our ﬁndings on naloxone use here is limited to participants who received reﬁlls.
DOPE Project staff made no attempts to actively follow up with other participants.
Therefore, we cannot determine an exact proportion of reversal, loss, or conﬁscation
among participants overall. It is similarly difﬁcult to draw conclusions about the
actual incidence of adverse effects following naloxone administration. Unfortu-
nately, we did not collect detailed information in our structured questionnaire about
the extent of the non-fatal adverse events. As such, we cannot know the extent of the
symptoms of seizures, which could have ranged from tonic-clonic activity to slight
alterations of consciousness. Individuals with positive experiences may have been
more likely to request reﬁlls than those with negative experiences using naloxone.
However, few adverse effects were reported, and the proportion of reported deaths
from unsuccessful reversals was similar to other NPP evaluations.
27,32,34
CONCLUSION
This is the ﬁrst longitudinal evaluation of participants, reﬁll request, naloxone use,
and outcomes among IDUs participating in a take-home naloxone prescription
program in San Francisco. Participation has grown steadily among individuals at
high risk of witnessing overdose events, and ﬁndings indicate that participants are
motivated to receive reﬁlls following naloxone loss or use. Among trained
participants who report using naloxone, nine in 10 report positive outcomes. Few
serious side effects or deaths were reported. The ﬁndings presented here add to a
growing body of evidence that supports the positive impact of NPPs as an
intervention to prevent potentially fatal overdose events.
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